Toggle Main Menu Toggle Search

Open Access padlockePrints

The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling

Lookup NU author(s): Dr Neil Rajan, Naomi Sinclair

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

CYLD, an ubiquitin hydrolase, has an expanding repertoire of regulatory roles in cell signalling and is dysregulated in a number of cancers. To dissect CYLD function we used a proteomics approach to identify CYLD interacting proteins and identified MIB2, an ubiquitin ligase enzyme involved in Notch signalling, as a protein which interacts with CYLD. Coexpression of CYLD and MIB2 resulted in stabilisation of MIB2 protein levels and was associated with reduced levels of JAG2, a ligand implicated in Notch signalling. Conversely, gene silencing of CYLD using siRNA, resulted in increased JAG2 expression and upregulation of Notch signalling. We investigated Notch pathway activity in skin tumours from patients with germline mutations in CYLD and found that JAG2 protein levels and Notch target genes were upregulated. In particular, RUNX1 was overexpressed in CYLD defective tumour cells. Finally, primary cell cultures of CYLD defective tumours demonstrated reduced viability when exposed to.-secretase inhibitors that pharmacologically target Notch signalling. Taken together these data indicate an oncogenic dependency on Notch signalling and suggest potential novel therapeutic approaches for patients with CYLD defective tumours.


Publication metadata

Author(s): Rajan N, Elliott RJR, Smith A, Sinclair N, Swift S, Lord CJ, Ashworth A

Publication type: Article

Publication status: Published

Journal: Oncotarget

Year: 2014

Volume: 5

Issue: 23

Pages: 12126-12140

Print publication date: 15/12/2014

Online publication date: 03/11/2014

Acceptance date: 03/10/2014

Date deposited: 09/03/2015

ISSN (electronic): 1949-2553

Publisher: Impact Journals LLC

URL: https://doi.org/10.18632/oncotarget.2573

DOI: 10.18632/oncotarget.2573

PubMed id: 25565632


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share